Stryker is well positioned for future growth through M&A activity and strong organic revenue and EPS growth. However, potential risks such as limited acquisition opportunities and potential expenses from tariffs and operating costs may affect the company's growth in the future.
Bears say
Stryker is a successful medical technology company with a strong product portfolio in orthopedics, medical and surgical, and neurotechnology. However, the recent decline in its leverage ratio, management's desire for M&A, and the lack of FDA clearance for IVL technology combined with the slowing organic revenue growth and margin performance in its bear case scenario calls for a negative outlook on the stock.
Stryker (SYK) has been analyzed by 15 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 47% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Stryker and is not a guaranteed prediction by Public.com or investment advice.
Stryker (SYK) Analyst Forecast & Price Prediction
Get the latest Stryker (SYK) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Analysts have given Stryker (SYK) a Buy based on their latest research and market trends.
According to 15 analysts, Stryker (SYK) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $400.07, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $400.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.
Stryker (SYK)
Stryker (SYK) Analyst Forecast & Price Prediction
Get the latest Stryker (SYK) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.